How much could long-acting PrEP cost in South Africa?

Lancet HIV. 2022 Dec;9(12):e814-e815. doi: 10.1016/S2352-3018(22)00293-4. Epub 2022 Nov 7.

Authors

Edinah Mudimu¹, Anna Bershteyn²

Affiliations

¹ Department of Decision Sciences, University of South Africa, Pretoria 0003, South Africa. Electronic address: mudime@unisa.ac.za.
² School of Medicine, New York University, New York, NY, USA.

PMID: 36356602
DOI: 10.1016/S2352-3018(22)00293-4

No abstract available

Publication types

Comment

MeSH terms

Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
HIV Infections* / epidemiology
HIV Infections* / prevention & control
Humans
Pre-Exposure Prophylaxis*
South Africa / epidemiology

Substances

Anti-HIV Agents